Clinical trial · Observational
Innovative 3D Preclinical Models for Mature B-cell Malignancies to Advance Personalized Immuno and Combination Therapies
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Adult patients with chronic lymphocytic leukemia (CLL), splenic marginal-zone lymphoma (SMZL) and hairy cell leukemia (HCL) followed at participating clinical sites will be enrolled and undergo sampling of additional amount of blood during the blood draws performed as part of standard clinical care. The project aims to develop and validate innovative patient-derived 3D bioprinted models that faithfully reproduce the key microenvironments of lymphoid tissues, enabling a more physiologically relevant study of mature B-cell malignancies.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Lymphocytic Leukemia (CLL) | Chronic Lymphocytic Leukemia | ALIAS | 0.90 |
| Hairy Cell Leukemia (HCL) | Hairy Cell Leukemia | ONTOLOGY_EXACT | 0.85 |
| Splenic Marginal Zone Lymphoma | Splenic Marginal Zone Lymphoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (3)
- label
- CLL
- description
- Patients diagnosed with CLL
- label
- SMZL
- description
- Patients diagnosed with SMZL
- label
- HCL
- description
- Patients diagnosed with HCL
Primary outcomes (1)
- measure
- To generate 3D culture models from patients with CLL, SMZL, HCL
- timeFrame
- 36 months
- description
- ≥50% 3D culture models generated from patients with CLL, SMZL and HCL, defined as cell viability \>80% per sample in standard condition
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥18 years * Diagnosis of CLL, SMZL or HCL * Participant is willing and able to autonomously give informed consent for participation in the study. Exclusion Criteria: \- Participant is unable or unwilling to provide informed consent for participation in the study
References
Publications (0)
Data not yet available